Trial reportGut2018
Dynamics of
Abstract readRandomized Controlled Trial
In one paragraph
Trial report in Gut, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 106 papers, 10 of them syntheses that pooled it.
0numbers the graph read from it
0cells of the map it votes in
106citing papers in PubMed, 10 pooled it
14.9field-weighted citation impact, top 1% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
106 citing papers in PubMed, 10 syntheses or guidelines pooled it, 173 citations in OpenAlex.
- Gastric cancer burden and regional disparities among Helicobacter pylori-positive patients in the Americas: a systematic review and meta-analysis.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2026Pooled it
- Asian Pacific Association of Gastroenterology task force recommendations on surveillance forGut · 2026Guideline
- From histological recovery to residual gastric cancer risk afterFrontiers in medicine · 2026Pooled it
- Quality indicators for upper GI endoscopy.Gastrointestinal endoscopy · 2025Guideline
- Long-term proton pump inhibitors use and its association with premalignant gastric lesions: a systematic review and meta-analysis.Frontiers in pharmacology · 2023Pooled it
- Increased Incidence and Mortality of Gastric Cancer in Immigrant Populations from High to Low Regions of Incidence: A Systematic Review and Meta-Analysis.Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association · 2020Pooled it
- AGA Technical Review on Gastric Intestinal Metaplasia-Natural History and Clinical Outcomes.Gastroenterology · 2020Pooled it
- Salivary MicroRNA for Diagnosis of Cancer and Systemic Diseases: A Systematic Review.International journal of molecular sciences · 2020Pooled it
- Pooled it
- Gastric cancer in patients with gastric atrophy and intestinal metaplasia: A systematic review and meta-analysis.PloS one · 2019Pooled it
- Safety and Efficacy of Eflornithine in Patients with Gastric Precancerous Lesions: A Double-Blinded, Randomized Clinical Trial.Cancer prevention research (Philadelphia, Pa.) · 2026Trial
- Randomized, Double-Blind, Placebo-Controlled Trial of Meriva (Curcuminoids) as a Candidate Chemoprevention Agent for Gastric Carcinogenesis.Cancer prevention research (Philadelphia, Pa.) · 2026Trial
- Establishment of a Mesoamerican-Caribbean South-South Research Platform: Challenges in the Meriva (Curcuminoids) Gastric Cancer Chemoprevention Trial.Cancer prevention research (Philadelphia, Pa.) · 2024Trial
- Yiwei Xiaoyu granules for treatment of chronic atrophic gastritis with deficiency syndrome of the spleen and stomach.World journal of clinical cases · 2024Trial
- The Colombian Chemoprevention Trial: 20-Year Follow-Up of a Cohort of Patients With Gastric Precancerous Lesions.Gastroenterology · 2021Trial
- Assessing the Malignant Potential of Gastric Mucosa Disorders: A Pilot Study on Lipid Peroxidation End Products and COX-2 Detection by Immunohistochemistry.Molecular carcinogenesis · 2026Article
- Bad bugs mean business: gastric cancer is an intended consequence ofInfection and immunity · 2026Review
- Reproducible Topographic Phenotypes and Three-Phase Anatomical Evolution of Gastric Intestinal Metaplasia.Digestive endoscopy : official journal of the Japan Gastroenterological Endoscopy Society · 2026Article
- Gastric intestinal metaplasia: unraveling the multifactorial pathogenesis and advancing risk stratification for gastric cancer prevention.Cellular and molecular life sciences : CMLS · 2026Review
- Animal models and pathogenesis of gastric cancer: from premalignant conditions-to-metastasis.Cancer biology & medicine · 2026Review
46 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
Authors and funding
14 authors at 4 institutions in 2 countries.
Robertino M MeraDepartment of Medicine, Division of Gastroenterology, Hepatology and Nutrition, Vanderbilt University Medical Center, Nashville, Tennessee, USA.
Luis E BravoDepartment of Pathology, Universidad del Valle School of Medicine, Cali, Colombia.
M Constanza CamargoDivision of Cancer Epidemiology and Genetics, National Cancer Institute, Rockville, Maryland, USA.
Juan C BravoDepartment of Pathology, Universidad del Valle School of Medicine, Cali, Colombia.
Alberto G DelgadoDepartment of Medicine, Division of Gastroenterology, Hepatology and Nutrition, Vanderbilt University Medical Center, Nashville, Tennessee, USA.
Judith Romero-GalloDepartment of Medicine, Division of Gastroenterology, Hepatology and Nutrition, Vanderbilt University Medical Center, Nashville, Tennessee, USA.
Maria C YepezCentro de Estudios en Salud, Universidad de Nariño, Pasto, Colombia.
José L RealpeCentro de Estudios en Salud, Universidad de Nariño, Pasto, Colombia.
Barbara G SchneiderDepartment of Medicine, Division of Gastroenterology, Hepatology and Nutrition, Vanderbilt University Medical Center, Nashville, Tennessee, USA.
Douglas R MorganDepartment of Medicine, Division of Gastroenterology, Hepatology and Nutrition, Vanderbilt University Medical Center, Nashville, Tennessee, USA.
Richard M PeekDepartment of Medicine, Division of Gastroenterology, Hepatology and Nutrition, Vanderbilt University Medical Center, Nashville, Tennessee, USA.
Pelayo CorreaDepartment of Medicine, Division of Gastroenterology, Hepatology and Nutrition, Vanderbilt University Medical Center, Nashville, Tennessee, USA.
Keith T WilsonDepartment of Medicine, Division of Gastroenterology, Hepatology and Nutrition, Vanderbilt University Medical Center, Nashville, Tennessee, USA.
M Blanca PiazueloDepartment of Medicine, Division of Gastroenterology, Hepatology and Nutrition, Vanderbilt University Medical Center, Nashville, Tennessee, USA.
Vanderbilt University Medical Center · USUniversidad del Valle · COUniversity of Nariño · CONational Cancer Institute · US
Funding
VANDERBILT UNIVERSITY CTSA FOR PEDIATRIC RESEARCHUL1RR024975 · NCRR · VANDERBILT UNIVERSITY · PI BERNARD, GORDON RAPHAEL · 2007 to 2011
$45.7MTranslational Analysis CoreP30DK058404 · NIDDK · VANDERBILT UNIVERSITY MEDICAL CENTER · PI RICHARD M. PEEK · 2002 to 2026
$29.9MRole of Iron and B-Catenin Activation in Gastric CarcinogenesisP01CA116087 · NCI · VANDERBILT UNIVERSITY MEDICAL CENTER · PI RICHARD M. PEEK · 2009 to 2026
$27.5MProject 3 - Molecular Signatures of Gastric Carcinogenesis in the Host Response to H. pyloriP01CA028842 · NCI · VANDERBILT UNIVERSITY MEDICAL CENTER · PI WILSON, KEITH T. · 1985 to 2019
$15.8MH.Pylori Relationship to Digestive Diseases and CancerR01CA077955 · NCI · VANDERBILT UNIVERSITY MEDICAL CENTER · PI RICHARD M. PEEK · 2003 to 2026
$9.7MTRAINING IN GASTROENTEROLOGYT32DK007673 · NIDDK · VANDERBILT UNIVERSITY MEDICAL CENTER · PI RICHARD M. PEEK · 1992 to 2026
$8.4MHelicobacter Pylori and Gastrointestinal BiologyR01DK058587 · NIDDK · VANDERBILT UNIVERSITY MEDICAL CENTER · PI PEEK, RICHARD M. · 2001 to 2024
$7.8MImmunomodulatory effects of arginine supplementation in colitis and colon cancerR01AT004821 · NCCIH · VANDERBILT UNIVERSITY MEDICAL CENTER · PI WILSON, KEITH T. · 2008 to 2017
$4.0MHPYLORI INDUCED DNA DAMAGE AND IMMUNE DYSREGULATIONR01DK053620 · NIDDK · VANDERBILT UNIVERSITY MEDICAL CENTER · PI WILSON, KEITH T. · 1997 to 2014
$3.4MTargeted chemoprevention of gastric carcinogenesis in high risk populationsR01CA190612 · NCI · VANDERBILT UNIVERSITY MEDICAL CENTER · PI MORGAN, DOUGLAS, WILSON, KEITH T. · 2014 to 2018
$3.0MMechanism that regulate Helicobacter pylori-induced beta-caterin activationR01DK073902 · NIDDK · VANDERBILT UNIVERSITY · PI PEEK, RICHARD M. · 2006 to 2009
$1.2MH PYLORI RELATIONSHIP TO DIGESTIVE DISEASES AND CANCERR29CA077955 · NCI · VANDERBILT UNIVERSITY · PI PEEK, RICHARD M · 1997 to 2001
$294kBLRD VA I01 BX001453NCCIH NIH HHS R01 AT004821NCI NIH HHS P01 CA028842NCI NIH HHS P01 CA116087NCI NIH HHS R01 CA077955NCI NIH HHS R01 CA190612NCI NIH HHS R29 CA077955NCRR NIH HHS UL1 RR024975NIDDK NIH HHS P30 DK058404NIDDK NIH HHS R01 DK053620NIDDK NIH HHS R01 DK058587NIDDK NIH HHS R01 DK073902NIDDK NIH HHS T32 DK007673
Abstract
objectiveTo evaluate the long-term effect of cumulative time exposed to
design795 adults with precancerous gastric lesions were randomised to receive anti-
resultsIndividuals who were continuously infected with
conclusionsLong-term exposure to
Indexed as
AdultAgedAnti-Bacterial AgentsDisease ProgressionDrug Administration ScheduleFemaleFollow-Up StudiesHelicobacter InfectionsHelicobacter pyloriHumansMaleMetaplasiaMiddle AgedPrecancerous ConditionsRisk FactorsStomach NeoplasmsAnti-Bacterial Agentsatrophydysplasiaeradicationgastric cancerH. pyloriintestinal metaplasiaLatin AmericaOLGAOLGIM
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.